Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
poziotinib + paclitaxel + trastuzumab
- Development stage
- Phase 2
- Lead developer
- Hanmi Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral (poziotinib), Intravenous (paclitaxel, Trastuzumab)
01
Overview
Poziotinib + paclitaxel + trastuzumab is an investigational combination therapy composed of three agents: poziotinib, a potent irreversible pan-HER tyrosine kinase inhibitor that targets EGFR, HER2 (ERBB2), and HER4 (ERBB4); paclitaxel, a microtubule stabilizing antineoplastic agent; and trastuzumab, a monoclonal antibody targeting the HER2 extracellular domain. This combination is primarily studied for the treatment of HER2-positive advanced gastric cancer, with poziotinib enhancing the efficacy of paclitaxel and trastuzumab by irreversibly inhibiting HER-family signaling pathways and overcoming resistance mechanisms via inhibition of ABCB1-mediated drug efflux. Paclitaxel disrupts microtubule dynamics and mitosis, while trastuzumab inhibits HER2 signaling, leading to growth arrest and apoptosis in HER2-overexpressing tumors.
- Brand names
- Herceptin (trastuzumab)Taxol (paclitaxel)
- Other names
- poziotinib + paclitaxel + trastuzumab
02
Targets
EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)ABCB1 (P-glycoprotein)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on poziotinib + paclitaxel + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on poziotinib + paclitaxel + trastuzumab.